Sedation in the intensive care unit with remifentanil/propofol versus midazolam/fentanyl: a randomised, open-label, pharmacoeconomic trial
-
* Corresponding author: Bernd Muellejans dr.muellejans@drguth.de
Critical Care 2006, 10:R91 doi:10.1186/cc4939
Accesses
- Last 30 days: 166 accesses
- Last year: 1505 accesses
- All time: 16710 accesses
Cited by
BioMed Central: 4 citations
|
Research
The incidence of sub-optimal sedation in the ICU: a systematic review Daniel L Jackson, Clare W Proudfoot, Kimberley F Cann, Tim S Walsh Critical Care 2009, 13:R204 (16 December 2009) |
|
Research
Remifentanil discontinuation and subsequent intensive care unit-acquired infection: a cohort study Saad Nseir, Jérémy Hoel, Guillaume Grailles, Aude Soury-Lavergne, Christophe Di Pompeo, Daniel Mathieu, Alain Durocher Critical Care 2009, 13:R60 (21 April 2009) Remifentanil discontinuation is associated with an increased risk of ICU-acquired infection, an observation that reiterates previous reports on the negative effects of opioid withdrawal on the immune system.
|
|
Review
The place for short-acting opioids: special emphasis on remifentanil Wolfram Wilhelm, Sascha Kreuer Critical Care 2008, 12(Suppl 3):S5 (14 May 2008) |
|
Research
Jörg Martin, Martin Franck, Stefan Sigel, Manfred Weiss, Claudia Spies Critical Care 2007, 11:R124 (6 December 2007) |